Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections

Basit Öğe Kaydı
dc.contributor.authorUney, Kamil
dc.contributor.authorAltan, Feray
dc.contributor.authorAboubakr, Mohammed
dc.contributor.authorCetin, Gul
dc.contributor.authorDik, Burak
dc.date.accessioned2024-04-24T17:18:53Z
dc.date.available2024-04-24T17:18:53Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractOBJECTIVE To determine the pharmacokinetics of meloxicam after single IV and IM injections in red-eared slider turtles (Trachemys scripta elegans). ANIMALS 8 healthy red-eared slider turtles. PROCEDURES Turtles received 1 dose of meloxicam (0.2 mg/kg) IV or IM (4 turtles/route), a 30-day washout period was provided, and then turtles received the same dose by the opposite route. Blood samples were collected at predetermined times for measurement of plasma meloxicam concentration. Pharmacokinetic values for each administration route were determined with a 2-compartment open model approach. RESULTS For IV administration, mean +/- SD values of major pharmacokinetic variables were 1.02 +/- 0.41 hours for distribution half-life, 9.78 +/- 2.23 hours for elimination half-life, 215 +/- 32 mL/kg for volume of distribution at steady state, 11.27 +/- 1.44 mu g.h/mL for area under the plasma concentration versus time curve, and 18.00 +/- 2.32 mL/h/kg for total body clearance. For IM administration, mean values were 0.35 +/- 0.06 hours for absorption half-life, 0.72 +/- 0.06 mu g/mL for peak plasma concentration, 1.5 +/- 0.0 hours for time to peak concentration, 3.73 +/- 2.41 hours for distribution half-life, 13.53 +/- 1.95 hours for elimination half-life, 11.33 +/- 0.92 mu g.h/mL for area under the plasma concentration versus time curve, and 101 +/- 6% for bioavailability. No adverse reactions were detected. CONCLUSIONS AND CLINICAL RELEVANCE Long half-life, high bioavailability, and lack of immediate adverse reactions of meloxicam administered IM at 0.2 mg/kg suggested the possibility of safe and effective clinical use in turtles. Additional studies are needed to establish appropriate administration frequency and clinical efficacy.en_US
dc.description.sponsorshipCoordination of Scientific Research Projects, University of Selcuk [14401041]en_US
dc.description.sponsorshipSupported by the Coordination of Scientific Research Projects, University of Selcuk (project No. 14401041).en_US
dc.identifier.doi10.2460/ajvr.77.5.439
dc.identifier.endpage444en_US
dc.identifier.issn0002-9645
dc.identifier.issn1943-5681
dc.identifier.issue5en_US
dc.identifier.pmid27111010
dc.identifier.scopus2-s2.0-84964461860
dc.identifier.scopusqualityQ2
dc.identifier.startpage439en_US
dc.identifier.urihttps://doi.org/10.2460/ajvr.77.5.439
dc.identifier.urihttps://hdl.handle.net/11468/18937
dc.identifier.volume77en_US
dc.identifier.wosWOS:000377079600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAmer Veterinary Medical Assocen_US
dc.relation.ispartofAmerican Journal of Veterinary Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titlePharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injectionsen_US
dc.titlePharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu